DOI: http://dx.doi.org/10.18203/2349-3933.ijam20211054

Serum fibroscores APRI, FIB-4 and fibroscan in assessment of liver fibrosis in alcoholic associated liver disease

B. Balakasi Naik, Babu Kumar, Sultan Nawahirsha Pughazhendhi

Abstract


Background: Alcohol-associated liver disease includes a variety of clinical disorders which include steatosis, Alcoholic steato hepatitis, alcoholic hepatitis of varying degrees of severity, alcoholic cirrhosis, and alcohol associated cirrhosis complicated by hepatocellular carcinoma (HCC). In patients with alcoholic liver disease the presence of hepatic (liver) fibrosis and progression into cirrhosis is a prognostic variable and having impact on survival. To assess hepatic (liver) fibrosis using serum fibro scores fibrosis-4 (FIB-4) scores, AST platelet ratio index (APRI scores) and to compare these results with fibro scan to rule out severe fibrosis in patients with alcohol related disease.

Methods: A cross sectional clinical study conducted on 50 patients with alcohol associated chronic liver disease between December 2019 to December 2020 who were in follow up in outpatient department (OPD) and admitted in the Department of Medical Gastroenterology. APRI and FIB-4 scores were calculated and compared with fibro scan values.

Results: The results of 50 patients were analysed, including, males with a mean age. Among the study population, 6 (12%) participants had no significant FIB-4, 16 (32%) participants had intermediate FIB-4 and 28 (56%) participants had likely cirrhosis. 33 (66%) participants had no significant APRI, 6 (12%) participants had significant APRI and 11 (22%) participants had cirrhosis liver. Among the people with fibro scan KPA F0-F1 (<7), all of them 100% were no significant FIB-4. Among the people with fibro scan KPA F2 (7 To 9.50), 2 (50%) were no significant FIB-4 and intermediate FIB-4 for each respectively.

Conclusions: FIB-4 score correlated better than APRI score in assessing patients with and without severe fibrosis and cirrhosis in the setting of alcohol associated liver disease patients.

 


Keywords


APRI, FIB-4, Fibro scan, Alcoholic associated liver disease

Full Text:

PDF

References


Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152:1544-77.

Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371-8.

Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2016;9:692-701.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol. 2019;70:133-41.

Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-62.

Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointest Liver Dis. 2010;19(1):53-60.

Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of non-alcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci. 2013;58(1):265-74.

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significantfibrosis inpatients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.

Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36.

Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection - noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Dig Liver Dis. 2019;51:183-9.

Rausch V, Peccerella T, Lackner C, Yagmur E, Seitz HK, Longerich T, et al. Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with the PNPLA3 variant I148M. World J Hepatol. 2016;8:1547-56.

Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015;13:27-36.

Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62:15-24.

Trivedi HD, Lin SC, Lau D. Noninvasive assessment of fibrosis regression in hepatitis C virus sustained virologic responders. Gastroenterol Hepatol. 2017;13:587-95.

Maiwall R, Kumar A, Bhardwaj A, Kumar G, Bhadoria AS, Sarin SK. Cystatin C predicts acute kidney injury and mortality in cirrhotics: a prospective cohort study. Liver International. 2018;38(4):654-64.

Zhu HD, Ma YC. Serum homocysteine as a prognostic biomarker for short-term mortality in HBV-related acuteon-chronic liver failure patients. Clin Lab. 2018;64(5):727-33.

Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66:610-8.

Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17:1877-85.

Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-55.

Zou D, Qi X, Zhu C, Ning Z, Hou F, Zhao J, et al. Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: A retrospective study. Turk J Gastroenterol. 2016;27(2):180-6.

Hazeldine S, Hydes T, Sheron N. Alcoholic liver disease - the extent of the problem and what you can do about it. Clin Med. 2015;15:179-85.

Filingeri V, Francioso S, Sforza D, Santopaolo F, Oddi FM, Tisone G. A retrospective analysis of 1.011 percutaneous liver biopsies performed in patients with liver transplantation or liver disease: ultrasonography can reduce complications? Eur Rev Med Pharmacol Sci. 2016;20:3609-17.

Piecha F, Peccerella T, Bruckner T, Seitz HK, Rausch V, Mueller S. Arterial pressure suffices to increase liver stiffness. Am J PhysiolGastrointest Liver Physiol. 2016;311:945-53.

Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016;65:1006-16.

Soto M, Sampietro-Colom L, Lasalvia L, Mira A, Jimenez W, Navasa M. Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. World J Gastroenterol. 2017;23:3163-73.

Mueller S. Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis. World J Gastroenterol. 2016;22:10482.

Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, et al. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. Hepatology. 2017;66:96-107.